蒂尔泽帕提德用于治疗阻塞性睡眠呼吸暂停和肥胖症
Atul Malhotra1, Ronald R Grunstein1, Ingo Fietze1
1From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney - all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, and Harvard Medical School - both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
蒂尔泽帕提德显著降低了中度至重度阻塞性睡眠呼吸暂停 (OSA) 和肥胖症的成年人的呼吸暂停-低呼吸暂停指数 (AHI) 和体重. 治疗还改善了其他健康标志物和患者报告的结果.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 睡眠医学 睡眠医学
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 与严重的心血管问题有关,肥胖是关键的危险因素.
- 蒂尔泽帕提德是一种潜在的治疗药物,目前正在研究其在治疗OSA方面的有效性.
研究的目的:
- 评估特泽帕提德在中度至重度阻塞性睡眠呼吸暂停和肥胖症的成年人中的有效性.
- 评估蒂尔泽帕提德对呼吸暂停-呼吸暂停指数 (AHI) 和其他相关健康参数的影响.
主要方法:
- 两项3期,双盲,随机对照试验在患有中度至重度OSA和肥胖症的成年人中进行.
- 参与者接受了蒂尔泽帕提德 (10毫克或15毫克) 或安慰剂52周,主要终点是AHI的变化.
主要成果:
- 与安慰剂相比,提尔泽帕提德在两项试验中都显示出AHI显著降低 (P<0.001).
- 治疗还导致体重,低氧负担,hsCRP水平,缩血压和患者报告的睡眠结果显著改善.
结论:
- 蒂尔泽帕提德有效地降低了中度至重度OSA和肥胖症患者的AHI和体重.
- 该药物在改善心血管风险因素和患者群体的睡眠质量方面表现有前途.
相关概念视频
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia
Antidepressant Drugs: MAOIs and Other Agents
Oral Hypoglycemic Agents: Biguanides and Glitazones
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...


